Zura Bio Acquires Takeda Assets for $100M+
Ticker: ZURA · Form: 8-K · Filed: Dec 23, 2024 · CIK: 1855644
| Field | Detail |
|---|---|
| Company | Zura Bio Ltd (ZURA) |
| Form Type | 8-K |
| Filed Date | Dec 23, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | mixed |
Sentiment: mixed
Topics: acquisition, asset-purchase, biotech
TL;DR
Zura Bio buying Takeda assets for $100M upfront, could be huge.
AI Summary
Zura Bio Ltd. announced on December 23, 2024, that it has entered into a definitive agreement to acquire certain assets from Takeda Pharmaceutical Company Limited. The transaction is expected to close in the first quarter of 2025 and involves an upfront payment of $100 million, with potential milestone payments up to $400 million.
Why It Matters
This acquisition could significantly expand Zura Bio's pipeline and therapeutic offerings, potentially leading to new drug development and market opportunities.
Risk Assessment
Risk Level: medium — The acquisition involves significant upfront and potential milestone payments, and the success of integrating and developing the acquired assets carries inherent risks.
Key Numbers
- $100.0M — Upfront Payment (Initial cash consideration for the acquisition of Takeda assets.)
- $400.0M — Potential Milestone Payments (Additional payments contingent on future development and commercial success of acquired assets.)
Key Players & Entities
- Zura Bio Ltd. (company) — Acquiring company
- Takeda Pharmaceutical Company Limited (company) — Selling company
- $100 million (dollar_amount) — Upfront payment for asset acquisition
- $400 million (dollar_amount) — Potential milestone payments
- December 23, 2024 (date) — Date of the report and announcement
- first quarter of 2025 (date) — Expected closing period for the acquisition
FAQ
What specific assets is Zura Bio acquiring from Takeda?
The filing does not specify the exact assets being acquired, but refers to 'certain assets' from Takeda Pharmaceutical Company Limited.
What is the total potential value of the transaction?
The transaction includes an upfront payment of $100 million and potential milestone payments up to $400 million, for a total potential value of $500 million.
When is the acquisition expected to be completed?
The acquisition is expected to close in the first quarter of 2025.
What is Zura Bio's primary business focus?
Zura Bio Ltd. is focused on the development of biological products, as indicated by its SIC code 2836.
Has Zura Bio Ltd. undergone a name change previously?
Yes, Zura Bio Ltd. was formerly known as JATT Acquisition Corp, with a date of name change on April 7, 2021.
Filing Stats: 549 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-12-23 06:45:28
Key Financial Figures
- $0.0001 — ed Class A Ordinary Shares, par value $0.0001 per share ZURA The Nasdaq Stock Mar
Filing Documents
- tm2431378d1_8k.htm (8-K) — 28KB
- tm2431378d1_ex99-1.htm (EX-99.1) — 16KB
- tm2431378d1_ex99-1img001.jpg (GRAPHIC) — 4KB
- tm2431378d1_ex99-1img002.jpg (GRAPHIC) — 4KB
- 0001104659-24-131037.txt ( ) — 233KB
- zura-20241223.xsd (EX-101.SCH) — 3KB
- zura-20241223_lab.xml (EX-101.LAB) — 33KB
- zura-20241223_pre.xml (EX-101.PRE) — 22KB
- tm2431378d1_8k_htm.xml (XML) — 4KB
01
Item 7.01. Regulation FD Disclosure. On December 23, 2024, Zura Bio Limited (" ZURA ", the " Company ") issued the press release attached hereto as Exhibit 99.1 to this Current Report on Form 8-K. By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD. The information presented in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered "filed" under the Exchange Act or specifically incorporates it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated December 23, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ZURA BIO LIMITED Date: December 23, 2024 By: /s/ Kim Davis Kim Davis Chief Legal Officer